HISTORIC LAUNCH TO LOWER DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced an expansion of TrumpRx.gov to provide unprecedented price transparency and choice on generic ...

Lupin is increasing its focus on complex generics, specialty medicines and differentiated products as global patent expiries create opportunities in regulated markets. The company reported growth in ...

If you've ever wanted to integrate OpenAI's ChatGPT features into your Java programs, you'll be happy to learn that Spring AI has made the process easier than ever. And it's not just easier to connect ...

Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%. Indian generic drugmakers have launched 26 ...

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams March 31 (Reuters) - Novo Nordisk on Tuesday cut the prices of its ...

Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production ...

Emory is the data editor at STAT. He’s a data journalist with a background in bioinformatics and molecular biology. You can reach Emory on Signal at jaspar.01. Elaine’s stories explore the boom in new ...

Section 1. Purpose. United States leadership in Artificial Intelligence (AI) will promote United States national and economic security and dominance across many domains. Pursuant to Executive Order ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...